Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Amylx Pharmaceuticals Inc (AMLX) vs TotalEnergies SE (TTE) Price & Performance

Amylx Pharmaceuticals IncTrade
TotalEnergies SETrade

Price performance (Past 24H)

Key statistics

Amylx Pharmaceuticals Inc vs TotalEnergies SE — how do they compare? Amylx Pharmaceuticals Inc trades at $23.65 (market cap $2.53B), while TotalEnergies SE trades at $86.9 (market cap $193.69B). The key difference: TotalEnergies SE is far larger — about 76.6× Amylx Pharmaceuticals Inc's market cap, and TotalEnergies SE pays a 4.82% dividend while Amylx Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.

AMLXTTE
Market Cap
$2.53B$193.69B
Sector
HealthEnergy
52-Week High
$24.19$93.60
52-Week Low
$7.82$57.39
Enterprise Value
$2.28B$224.68B
Dividend Yield
4.82%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Amylx Pharmaceuticals Inc

AMLX trades at $22.82, down 5.66% on the day, with a bullish technical signal from moving averages and key support at $22. The company reported a net loss of -$144.74M for 2025, with negative ROE and ROA, but holds a $250.8M cash runway into 2028. The pivotal Phase 3 LUCIDITY trial for avexitide is set for a late August/early September 2026 readout, a key near-term catalyst.

Analyst consensus is strongly bullish with a $30.00 price target, though recent earnings misses and negative cash flow from operations in 2026 pose risks. The stock's outlook hinges on successful clinical trial results and the subsequent regulatory pathway for its lead endocrine asset.

TotalEnergies SE

TotalEnergies (TTE) trades at $85.83, down 0.51% on the day, with a neutral technical signal. The stock shows attractive valuation metrics, including a P/E of 10.74 and P/S of 0.96, while recent earnings beat expectations in Q1 and Q2 2026. The company is actively reshaping its portfolio, acquiring Shell's European renewables business and developing the Cronos gas field in Cyprus. Cash flow improved in 2025, with net cash flow turning positive to $358 million after two years of outflows.

The outlook is supported by a strong analyst consensus, with a $94 price target and 57.6% buy ratings, but risks include declining revenue trends, legal challenges from climate litigation, and exposure to volatile energy markets. The stock offers a compelling value proposition with solid profitability and strategic investments in both traditional and renewable energy.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Amylx Pharmaceuticals Inc

Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.

Read more on AMLX

About TotalEnergies SE

TotalEnergies is an integrated oil and gas company that explores for, produces, and refines oil around the world. In 2021, it produced 1.5 million barrels of liquids and 7.2 billion cubic feet of natural gas per day. At year-end 2020, reserves stood at 12.1 billion barrels of oil equivalent, 45% of which are liquids. During 2021, it had LNG sales of 42 Mt. The company owns interests in refineries with capacity of nearly 1.8 million barrels a day, primarily in Europe, distributes refined products in 65 countries, and manufactures commodity and specialty chemicals. It also holds a 19% interest in Russian oil company Novatek. At year-end, its gross installed renewable power generation capacity was 10.3 GW.

Read more on TTE